Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.61 |
| ▸ | DRD3 | P35462 | 19/20 | 0.61 |
| ▸ | DRD4 | P21917 | 4/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193606 | 0.85 | DRD2 (0.67) | DRD2DRD3DRD4DRD5OPRK1 | |
| SCHEMBL2782099 | 0.84 | DRD2 (0.61) | DRD2DRD3DRD4DRD5 | |
| SCHEMBL1193746 | 0.82 | DRD2 (0.72) | DRD2DRD3DRD4 | |
| SCHEMBL644477 | 0.81 | DRD2 (0.59) | DRD2DRD3DRD4 | |
| SCHEMBL644476 | 0.81 | DRD2 (0.59) | DRD2DRD3DRD4 | |
| SCHEMBL14494815 | 0.80 | DRD2 (0.69) | DRD2DRD3DRD4DRD5 | |
| SCHEMBL14494898 | 0.79 | DRD2 (0.67) | DRD2DRD3DRD4DRD5 | |
| SCHEMBL14494921 | 0.79 | DRD2 (0.77) | DRD2DRD3DRD4DRD5OPRK1 | |
| SCHEMBL2785894 | 0.79 | DRD2 (0.77) | DRD2DRD3DRD4DRD5 | |
| SCHEMBL2096264 | 0.79 | DRD2 (0.67) | DRD2DRD3DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | DRD2 16/4885DRD3 41/4885DRD4 40/4885 |
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | DRD2 2/4885DRD3 7/4885DRD4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.